88933-16-8 N-Methyl-4-diazanylsulfabenzamide 98%

THE STORY SO FAR

The year 1994

Porus was started with one manufacturing location in the year 1994 to manufacture N-Acetyl Sulphanilyl Chloride (N-ASC), which is a key intermediate for all Sulpha based drugs.

The year 1998

With strong technology back up and aggressive marketing the company became the largest source of N-ASC in India displacing the then market leader tama, a Japanese company. The second unit was added in 1998 by taking over a sick unit at Bibinagar about 40 kms from Hyderabad to manufacture sulphamethaxazole, which was a natural integration forward to the intermediate N-ASC. However due to unfavorable market conditions the project was dropped. However the unit continued to support domestic API manufacturers for their intermediates like QAcid-Ciprofloxacin intermediate (40 Mt/month).

The year 1999

The third unit was added in the year 1999 at Kodad on the Vijayawada highway, another sick unit taken over and turned around to meet the growing demand of NASC (300 Mt/month) and other intermediates like Iso Butyl Acetophenone – Ibuprofen intermediate (120 Mt/month) etc.

The year 2000

Around the year 2000 R&D was started at Jeedimetla to develop our own intermediates with efficient processes with emphasis on antimigraine category of drugs called triptans. Since then porus has come to be known as the worldwide leader in this category and enjoys significant market share in the domestic market catering to customers like DR.REDDYS, SUNPHARMA, LUPIN, TEVA etc.

The year 2006

The acquisition of our fourth unit happened in the year 2006 to cater to the speciality chemicals business that had just started to shape up with our efforts in R&D. Using our extensive knowledge both in process as well as scale up we could grow this business. Today this is growing at about 50% yoyo with strong product line.

The year 2013

We have started commencement of work at our Unit-V, Pharmacity, Visakhapatnam with strong emphasis on APIs. We are in the process of building the state of the art API manufacturing facility which will commence production from the mid of 2014.